Best Safest Stocks For 2019

Things aren’t going to script right now in the financial sector. It’s a widely established fact (based on years of historical evidence) that banks and other lenders typically prosper when interest rates are rising. In previous rate-tightening cycles, the financial sector was usually among the market’s top performers.

—Recommended Link— Create A 10%+ Income Stream For Life
We’re sitting on a collection of the safest, most generous monthly payers available. And while $11,200 in dividend checks is a welcome addition to anyone’s income, investors also love racking up capital gains as high as 446%. Start generating a 10%+ income stream for life today from these consistent companies.

As I’ve discussed before in my High-Yield Investing premium newsletter, banks can feast in these conditions because the rates they charge borrowers on loans usually rise faster than the rates they pay to depositors. That widens net interest margins (NIMs) and fattens the bottom line.

Best Safest Stocks For 2019: NIC Inc.(EGOV)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of NIC (NASDAQ:EGOV) from a buy rating to a strong-buy rating in a research note published on Friday morning.

    Several other research firms also recently commented on EGOV. Zacks Investment Research downgraded NIC from a hold rating to a sell rating in a report on Monday, January 8th. ValuEngine downgraded NIC from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Barrington Research restated a hold rating on shares of NIC in a report on Monday, April 30th. TheStreet downgraded NIC from a b- rating to a c rating in a report on Thursday, March 8th. Finally, Loop Capital decreased their price objective on NIC to $14.00 and set a hold rating for the company in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $18.33.

  • [By Max Byerly]

    Shares of NIC Inc. (NASDAQ:EGOV) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $18.00.

  • [By Joseph Griffin]

    Media headlines about NIC (NASDAQ:EGOV) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NIC earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the software maker an impact score of 44.2220263592641 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Joseph Griffin]

    NIC Inc. (NASDAQ:EGOV) has been given a consensus recommendation of “Hold” by the ten research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

Best Safest Stocks For 2019: Western Asset Mortgage Capital Corporation(WMC)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine lowered shares of Western Asset Mortgage Capit (NYSE:WMC) from a buy rating to a hold rating in a research report report published on Wednesday.

Best Safest Stocks For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed most recently at $36.18, with a consensus price target of $57.38 and a 52-week range of $15.97 to $40.65.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

Best Safest Stocks For 2019: Infinity Pharmaceuticals, Inc.(INFI)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine upgraded shares of Infinity Pharmaceuticals (NASDAQ:INFI) from a sell rating to a hold rating in a report published on Saturday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.

Best Safest Stocks For 2019: Royal Dutch Shell PLC(RDS.A)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    Much of Wall Street will tell you to stick with the oil industry giants – companies like Exxon Mobil Corp. (NYSE: XOM) or Royal Dutch Shell Plc. (NYSE: RDS.A).

Top Low Price Stocks To Own For 2019

Private equity shops thought they saw a sure-fire way to make a buck: build dozens of new power plants fueled by cheap Appalachian natural gas to replace old coal-fired units.

It hasn’t quite turned out that way, at least not yet. Many of the new plants built in the last few years aren’t kicking off as much cash as the buyout firms had expected, according to bankers. There’s not enough demand to support the huge amount of additional new capacity, driving down electricity prices. And with President Donald Trump as a booster, shutdowns of coal haven’t come as quickly as anticipated while states are acting to keep nuclear plants open.

None of the new plants appear in danger of default, analysts said. But several plant owners are now using most of the extra cash they are generating to pay down debt.

Moreover, low prices and the results of a closely watched regional power-price auction scheduled for Wednesday could force many of the gas-fired plants built in the last five years to refinance their debt. At least one new U.S. plant, owned in part by an arm of private equity firm Ares Management LP, recently did so.

Top Low Price Stocks To Own For 2019: DigitalGlobe, Inc(DGI)

Advisors’ Opinion:

Top Low Price Stocks To Own For 2019: Patterson-UTI Energy, Inc.(PTEN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Thrivent Financial for Lutherans increased its stake in Patterson-UTI (NASDAQ:PTEN) by 31.8% during the 1st quarter, Holdings Channel reports. The firm owned 3,073,057 shares of the oil and gas company’s stock after purchasing an additional 741,573 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Patterson-UTI were worth $53,810,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Patterson-UTI Energy (PTEN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    First Pacific Advisors LLC decreased its holdings in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) by 15.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,451,909 shares of the oil and gas company’s stock after selling 273,567 shares during the quarter. First Pacific Advisors LLC owned 0.65% of Patterson-UTI Energy worth $25,423,000 at the end of the most recent reporting period.

Top Low Price Stocks To Own For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

Best Blue Chip Stocks To Buy Right Now

Shutterstock

Today I’m going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too.

I’ll also reveal a blue chip stock that’s delivering both strong price gains and rising dividends. It will have you pocketing a nice 5%+ yield in short order.

So let’s get going, starting with…

The Dividend-Growth Signal Most People Miss

If you’ve been buying dividend stocks for a while, you probably know about the payout ratio.

It’s a sacred cow for many folks; you calculate it by dividing the total amount of dividends paid by the company’s last 12 months of net income.

If it comes out in the neighborhood of, say, 50% or less, you’ve got a safe dividend that’s likely to grow. As you get climb closer to 100%, the noose around the payout gets tighter.

Best Blue Chip Stocks To Buy Right Now: Skyworks Solutions, Inc.(SWKS)

Advisors’ Opinion:

  • [By ]

    We’ve bagged winners like the 64.3% return from Mastercard (NYSE: MA), 44.3% from Intel (Nasdaq: INTC), 38.9% from Deere (NYSE: DE) and even 101.8% from Skyworks Solutions (Nasdaq: SWKS). So it’s easy to see why this has become one of StreetAuthority’s most popular reports.

  • [By Harsh Chauhan]

    More importantly, Apple could build around 120 million new iPhones this year as compared to 89 million units of the iPhone 7/7S in 2016 — according to Mizuho. This is great news for the other companies in Cupertino’s supply chain — such as Skyworks Solutions (NASDAQ:SWKS), Broadcom (NASDAQ:AVGO), and Cypress Semiconductor (NASDAQ:CY) — as they won’t have to wait until the second half of the year to bask in iPhone-driven glory.

  • [By WWW.THESTREET.COM]

    But Skyworks  (SWKS) reported a remarkable quarter, yet it’s getting hit.

    It showed some terrific Internet of Things orders and not just Apple  (AAPL) and Samsung, although both are excellent customers in a very big year.

  • [By Ben Levisohn]

    Skyworks Solutions (SWKS) soared to the top of the S&P 500 today after beating first-quarter earnings forecasts, and offering above-consensus second-quarter guidance.

    Getty Images

    Skyworks Solutions gained 13% to $88.67, while the S&P 500 rose 0.3% to 2,271.31.

    Oppenheimer’s Rick Schafer and team argue that Skyworks’ “growth [is] back on track.” They explain:

    We expect Skyworks to deliver above-market growth driven by 1) continued smartphone content gains; 2) China share gains through strengthening baseband partnerships and demand for integrated (vs. discrete) RF solutions; 3) seasonal uptick at Samsung; and 4) continued double-digit RF complexity increases. With its “one-stop-shop” systems-level approach, we seeSkyworks uniquely positioned to benefit from rising RF content. We reiterate Outperform and raise PT to $105 from $100.

    Skyworks Solutions’ market capitalization rose to $16.5 billion today from $14.6 billion yesterday.

  • [By Benzinga News Desk]

    Former President George H.W. Bush has been hospitalized in Houston with an infection, just after attending the funeral of his wife, Barbara, a spokesman said Monday: Link

    ECONOMIC DATA
    Redbook Reports US Retail Sales During First 2 Weeks Of Apr. Up 0.3% MoM, Up 2.8% YoY
    USA S&P/CaseShiller House Price Index (MoM) for Feb Up 0.7% MoM
    New home sales report for March will be released at 10:00 a.m. ET.
    The Conference Board’s consumer sentiment index for April is schedule for release at 10:00 a.m. ET.
    The Richmond Fed manufacturing index for April will be released at 10:00 a.m. ET.
    The Treasury is set to auction 4-and 52-week bills at 11:30 a.m. ET.
    The Treasury will auction 2-year notes at 1:00 p.m. ET.
    ANALYST RATINGS
    Leerink upgraded Cardinal Health (NYSE: CAH) from Market Perform to Outperform
    Berenberg upgraded Emerson Electric (NYSE: EMR) from Sell to Hold
    Mizuho downgraded Skyworks (NASDAQ: SWKS) from Buy to Neutral
    BMO downgraded Texas Roadhouse (NASDAQ: TXRH) from Outperform to Market Perform

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Rich Smith]

    Is that good news or bad news for Apple? According to a different analyst today, the answer to that question is beside the point: The one thing Mizuho Securities is sure of is that this is bad news for Skyworks Solutions (NASDAQ:SWKS).

Best Blue Chip Stocks To Buy Right Now: Regions Financial Corporation(RF)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Regions Financial (RF) , Edwards Lifesciences (EW) , Qualys (QLYS) and HEICO (HEI) .

  • [By ]

    Regions Financial (NYSE: RF) could be a beneficiary of the move to deregulation in banking this year and is expected to grow earnings by 24% to $1.35 per share. The bank is seeing strong growth in non-interest income sources and management has a plan to cut up to 10% in operating expenses for greater profitability. Regions has a strong deposit base across the Southeast and averages a 7% return on equity, well above the industry average.

  • [By ]

    Regions Financial (RF) : “I think this one is real good. I like the banks here.”

    Edwards Lifesciences (EW) : “They have the best devices. That stock is a buy.”

  • [By Sean Williams]

    Income investors often turn to bank stocks when looking for a steady dividend, but few offer the dividend growth potential of Southeastern regional bankRegions Financial (NYSE:RF).

Best Blue Chip Stocks To Buy Right Now: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By ]

    Aimmune Therapeutics (AIMT) : “I do like it. That’s an important niche business. “

    Ingersoll-Rand (IR) : “I like Ingersoll-Rand. They work well at this phase in the cycle.”

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Best Blue Chip Stocks To Buy Right Now: Washington Trust Bancorp, Inc.(WASH)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Best Blue Chip Stocks To Buy Right Now: Washington Federal, Inc.(WAFD)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    The six companies that met the criterion are:

    Oshkosh Corp (NYSE: OSK). Phillips 66 (NYSE: PSX). SpartanNash Co (NASDAQ: SPTN). Suncor Energy Inc. (USA) (NYSE: SU). Washington Federal Inc. (NASDAQ: WAFD). Barnes & Noble, Inc. (NYSE: BKS).
    Oshkosh

    Oshkosh is a manufacturer of specialty vehicles and vehicle bodies and is based in Wisconsin. The company operates under four business segments, namely access equipment, defense, fire and emergency, and commercial.

Best Blue Chip Stocks To Buy Right Now: Quidel Corporation(QDEL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Quidel Corporation (NASDAQ: QDEL) shares were also up, gaining 8 percent to $44.31. Piper Jaffray upgraded Quidel from Neutral to Overweight.

    Equities Trading DOWN

Top 5 Bank Stocks For 2018

Eldorado Resorts (NASDAQ:ERI) has been given a consensus rating of “Buy” by the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $41.56.

A number of equities research analysts have commented on ERI shares. Jefferies Group started coverage on Eldorado Resorts in a report on Thursday, January 18th. They issued a “buy” rating and a $40.00 target price for the company. BidaskClub downgraded Eldorado Resorts from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Zacks Investment Research downgraded Eldorado Resorts from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 20th. Roth Capital started coverage on Eldorado Resorts in a report on Tuesday, February 20th. They issued a “buy” rating and a $41.00 target price for the company. Finally, SunTrust Banks reissued an “average” rating and issued a $36.00 target price on shares of Eldorado Resorts in a report on Monday, February 5th.

Top 5 Bank Stocks For 2018: Henry Schein, Inc.(HSIC)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Henry Schein, Inc. (NASDAQ: HSIC) which rose over 6% to $73.68. The stocks 52-week range is $62.56 to $93.50. Volume was 3.3 million compared to the daily average volume of 1.9 million.

Top 5 Bank Stocks For 2018: Sharp Corp (SHCAF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The company is partnering with Chinese company OXi Technology (in which it also made a strategic investment) for developing fingerprint sensor under glass and in the bezel of smartphones. Its fingerprint sensor business received a boost from the Samsung (OTC:SSNLF) S8 and S8+ design wins (as well as Sharp’s (OTCPK:SHCAF) Aquos R and ZTE ZMax Pro).

Top 5 Bank Stocks For 2018: Williams Partners L.P.(WPZ)

Advisors’ Opinion:

  • [By Ben Levisohn]

    In a release after the close on Monday, Williams and Williams Partners (WPZ) made several announcements, including: 1) outlining managements plan to financially reposition and simplify the franchises GP/LP structure in an ~$11.4 billion transaction (not subject to any additional approvals), 2) adjustments to Williams and Williams Partners’ dividend and distribution payouts, 3) initiating a ~$2+ billion William equity raise to fund a further Williams investment in Williams Partners, 4) noted other potential upcoming changes, including the sale of ~$2 billion in non-core assets in 2017, and 5) provided several forms of updated 2017 guidance…

Top 5 Bank Stocks For 2018: EV Energy Partners, L.P.(EVEP)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
    My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
    DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
    CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
    China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
    Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
    Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
    Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
    Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
    EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

  • [By William Romov]

    Before we show you our pick, here are the top 10 penny stocks to watch this week

    Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
    Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
    Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
    Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
    UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
    WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
    PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
    EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
    Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free

Top 5 Bank Stocks For 2018: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Shares of Aimmune Therapeutics Inc (NASDAQ: AIMT) got a boost, shooting up 35 percent to $34.73 in response to failed DBVT peanut allergy trial.

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Jim Robertson]

    Small cap clinical-stage biopharmaceutical stock Aimmune Therapeutics (NASDAQ: AIMT) is aclinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune Therapeutics first investigational biologic product using CODITâ’™is AR101 for the treatment of peanut allergy.AR101 has received the FDAs Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials where enrollment was announced last month.

Top 10 Blue Chip Stocks To Invest In 2019

Shutterstock

Dont take any dividends for granted today. Business disruption is accelerating as entire industries are being eaten alive.

Uber and Lyft? Killed cabs.

Amazon (AMZN)? Its crushing retail, and starving their REIT landlords right before our very eyes.

And soon, they might team up to offer more same day deliveries and make more rivals obsolete!

These types of disturbances have added a new layer to contrarian investing. Before, it was as simple as buying stocks when they were out-of-favor and holding them until they became back in vogue. The Dogs of the Dow strategy, for example, usually beat the market by banking the highest blue chip dividend yields a sign that the tide was ready to turn back in the dogs favor.

Top 10 Blue Chip Stocks To Invest In 2019: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Blue Chip Stocks To Invest In 2019: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 2.9% Monday to post a new 52-week low of $2.35. Shares closed at $2.42 on Friday and the stock’s 52-week high is $4.25. Volume was about 10% below the daily average of around 5.8 million shares. The gold mining company had no news.

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 3.8% Thursday to post a new 52-week low of $2.28. Shares closed at $2.37 on Wednesday and the stock’s 52-week high is $4.25. Volume was about 15% below the daily average of around 5.9 million shares. The company had no specific news.

Top 10 Blue Chip Stocks To Invest In 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By David Zeiler]

    Bill Patalon’s initial stock pick was Galapagos NV (Nasdaq ADR: GLPG), a Belgian biotech company.

    Patalon was attracted to Galapagos’ strategy to target “orphan diseases,” afflictions that strike rarely and so often go ignored by the Big Pharma companies. He also liked that Galapagos had more than 50 drug discovery programs underway, and that it already had licensing agreements with several bigger players in the industry.

  • [By Stephen Mack]

    Our investing experts have made some tremendous picks over the last several years, outperforming the S&P 500 by 100%, 200%, or even as much as 700% in the case of Money Morning Executive Editor Bill Patalon’s 2012 pick of Galapagos NV (Nasdaq: GLPG).

  • [By Stephen Mack]

    Galapagos NV (Nasdaq: GLPG) is our big winner so far, gaining 578.8% since Money Morning Executive Editor Bill Patalon shared his recommendation with Money Morning readers in April 2012. The S&P 500 has gained 75.4% in the same time. Bill has renewed his recommendation for the Belgian biotech several times over the years, saying in 2016 that it has “an established history of piling on gains.” With an average gain of 110% a year, it’s hard to argue with that.

Top 10 Blue Chip Stocks To Invest In 2019: lululemon athletica inc.(LULU)

Advisors’ Opinion:

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) will report its most recent quarterly results on Wednesday as well. The consensus estimates are EPS of $0.52 and $609.71 million in revenue. Shares traded at $67.22 on Friday, in a 52-week range of $47.26 to $72.70. The consensus price target is $65.50.

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) is set to release its most recent quarterly results on Tuesday. The consensus forecast calls for $1.27 in EPS and $911.42 million in revenue. Shares traded on Fridays close at $79.51. The consensus price target is $84.33, and the 52-week range is $47.26 to $83.98.

  • [By Lisa Levin]

    Shares of Lululemon Athletica inc. (NASDAQ: LULU) got a boost, shooting up 15 percent to $68.99 after the company reported stronger-than-expected earnings for its third quarter and announced a $100 million stock buyback plan.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU) reported Q2 2017 earnings after the Thursday market close with results toppingexpectations as online sales surged 30% after an effort to beef up the eCommerce strategy plus the Company raised its outlook. Net revenuegrew 13% to$581.1 millionas total comparable sales increased 7% and comparable store sales increased 2%, or increased by 2% on a constant dollar basis. Direct to consumer net revenue increased 29%, or increased 30% on a constant dollar basis. During the quarter the Company held an online warehouse sale. Excluding the impact of this sale, direct to consumer net revenue increased 15%, or increased 16% on a constant dollar basis. Net income was $48.711 million versus net income of $53.625 million. The Company ended the second quarter of fiscal 2017 with $721.2 million in cash and cash equivalents compared to $535.3 million at the end of the second quarter of fiscal 2016. The CEO commented:

  • [By Paul Ausick]

    Lululemon Athletica Inc. (NASDAQ: LULU) reported fiscal second-quarter 2017 results after markets closed Thursday afternoon. The yoga gear maker reported adjusted diluted earnings per share (EPS) of $0.39 on revenues of $581.1 million, compared with EPS of $0.38 on revenues of $514.5 million in the same period a year ago. The consensus estimates called for EPS of $0.35 on revenues of $567.6 million.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU)reported earnings for the first quarter ended April30, 2017along witha plan to restructure its ivivva operations. Net revenuerose 5% to$520.3 millionas total comparable sales decreased 1% whiledirect to consumer net revenue was flat. Net income was $31.246 million versus $45.336 million. In addition, the earnings report stated:

Top 10 Blue Chip Stocks To Invest In 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aimmune Therapeutics Inc (NASDAQ: AIMT) got a boost, shooting up 35 percent to $34.73 in response to failed DBVT peanut allergy trial.

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

  • [By Jim Robertson]

    Small cap clinical-stage biopharmaceutical stock Aimmune Therapeutics (NASDAQ: AIMT) is aclinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune Therapeutics first investigational biologic product using CODITâ’™is AR101 for the treatment of peanut allergy.AR101 has received the FDAs Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials where enrollment was announced last month.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Top 10 Blue Chip Stocks To Invest In 2019: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.

    Agence France-Presse/Getty Images

    Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.

    Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:

    In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.

    Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.

    This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today as weakness that began last month even before its fourth-quarter earnings continued into year end.

    Agence France-Presse/Getty Images

    Mallinckrodtdropped 2.7% to $51.77 today, while the S&P 500 rose 0.2% to 2,268.88.

    Mallinckrodt was the biggest loser in the S&P 500 for two consecutive days in mid-November, and again after reporting its earnings.

    Mallinckrodt’s market capitalization fell to $5.5 billion today from $5.6 billion yesterday. It reported net income of $489 million on sales of $3.38 billion in fiscal 2016.

    Mallinckrodt has dropped 31% so far this year.

  • [By Johanna Bennett]

    Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.

    Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.

    Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.

    Also, he argues that Mallinckrodt continues to be misunderstood by investors.

    Goodman goes into goes into more detail:

    we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.

    Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.

  • [By Keith Speights]

    That’s the question investors are trying to answer about how President Trump’s policies might impact healthcare stocks. So far, specific policy proposals put forward by the president appear likely to cause significant problems for certain healthcare stocks. Here’s why three of President Trump’s policies could be downright terrible for Molina Healthcare(NYSE:MOH), Mallinckrodt (NYSE:MNK), and Illumina (NASDAQ:ILMN).

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.

    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe

Top 10 Blue Chip Stocks To Invest In 2019: Apollo Education Group, Inc.(APOL)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q1 2017 earnings report for small cap for-profit education stock Apollo Education Group Inc (NASDAQ: APOL) is scheduled for after the market closes on Monday (January 9th). Last February, Apollo Education Groupannounced a definitive agreement to be acquired by a consortium of investors including The Vistria Group, LLC, funds affiliated with Apollo Global Management, LLC (NYSE: APO), and Najafi Companies for $9.50 per share in cash for both Class A and B shares. However, the for-profit education sector along with certain aspects of the Apollo deal have been targeted by the Obama administration and it remains to be seen how the Trump administration will treat the sector and the deal.

Top 10 Blue Chip Stocks To Invest In 2019: Bloomin' Brands, Inc.(BLMN)

Advisors’ Opinion:

  • [By CNBC]

    Tony Tribble, Invision/AP
    Forget about Bloomin’ Onions or boneless wings, for many consumers, the choice of where to dine often comes down to a different factor: which restaurant has the best booze.
    “Alcoholic beverages can be a key driver of traffic, differentiation, and loyalty,” said David Decker, president of Consumer Edge Insight. According to the firm, two factors that keep customers coming back are “selection” and “pricing.”
    Consumer Edge Insight recently surveyed restaurant customers to find out which casual-dining spots generated the most loyalty with their alcoholic beverages.
    Taking the top spot for “selection” was Buffalo Wild Wings (BWLD), with 29 percent of those surveyed saying they were “most likely to visit it most often due to its good selection of alcoholic beverages.”
    Applebee’s (DIN) took the second spot, with 24 percent, and Outback Steakhouse (BLMN) and T.G.I. Friday’s tied for third place with 22 percent each.
    Prices also keep customers coming back to Buffalo Wild Wings.

    When asked which casual-dining brand they were “most likely to visit most often due to its good prices of alcoholic beverages,” Buffalo Wild Wings came out on top with 30 percent. Chili’s (EAT) was No. 2 at 23 percent, and Ruby Tuesday (RT) was third with 22 percent.
    Buffalo Wild Wings has always made alcohol a part of its experience, even making it part of its tagline: “Wings.Beer.Sports.”
    The chain is the No. 1 account for more than 50 different beer brands and recently launched Game Changer, a new beer in a partnership with Redhook Brewery. Priced between cheaper domestic lagers and pricier craft beers, Game Changer became the fourth-most-popular draft beer at company-owned locations within two weeks of its release.
    “Among casual-dining restaurants, Buffalo Wild Wings is seeing the greatest positive effect in terms of building customer loyalty with its alcohol offerings,” Decker said. “There are many steps other restaurants can take to improve their alcoho

Top 10 Blue Chip Stocks To Invest In 2019: Cellect Biotechnology Ltd. (APOP)

Advisors’ Opinion:

  • [By Chris Lange]

    Cellect Biotechnology Ltd. (NASDAQ: APOP) reported that it received a formal notice from the U.S. Patent and Trademark Office (USPTO)regarding its method of treatment for immune related disorders. Basically, the USPTO gave a notice of allowance which broadly means the agency intends to issue a patent approval. The treatment method relates to the engineering of regulatory immune cells with enhanced apoptotic activity used for the treatment or prevention for the unmet needs seen in type 1 diabetes, inflammatory bowel disease, graft versus host disease, and transplant rejection.

  • [By Lisa Levin]

    Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ: APOP) shares were also up, gaining 135 percent to $7.79 after the company disclosed that it has received a notice of allowance from the US Patent Office protecting its technology in multiple key indications.

Top 10 Blue Chip Stocks To Invest In 2019: Smith & Wesson Holding Corporation(SWHC)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming volatile higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker TASER International, Inc (NASDAQ: TASR):

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming more volatile and higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker Axon Enterprise (NASDAQ: AAXN), formerlyTASER International, Inc (NASDAQ: TASR):

  • [By Lisa Levin]

    Shares of Smith & Wesson Holding Corp (NASDAQ: SWHC) were down 12 percent to $21.04. Smith & Wesson reported upbeat results for its second quarter, but issued a weak outlook for its third quarter.

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming more volatile but higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker Axon Enterprise (NASDAQ: AAXN), formerlyTASER International, Inc (NASDAQ: TASR):

  • [By Chris Lange]

    Smith & Wesson Holding Corp. (NASDAQ: SWHC) reported fiscal second-quarter financial results after markets closed on Thursday. The company said that it had $0.68 in earnings per share (EPS) and $233.5 million in revenue, versus consensus estimates from Thomson Reuters called for $0.56 in EPS and $227.61 million in revenue. The same period from last year had $0.25 in EPS and $143.24 million in revenue.